☆ 4.3 Article

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions

LUPUS (2011)

Journal

LUPUS

Volume 20, Issue 2, Pages 165-173

Publisher

SAGE PUBLICATIONS LTD

DOI: 10.1177/0961203310395051

Keywords

Catastrophic antiphospholipid syndrome; nephropathy; heart valve lesions; antiphospholipid antibodies

Categories

Rheumatology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

The objectives of the 'Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations' were to assess the clinical utility of the international consensus statement on classification criteria and treatment guidelines for the catastrophic APS, to identify and grade the studies that analyse the relationship between the antiphospholipid antibodies and the non-criteria APS manifestations and to present the current evidence regarding the accuracy of these non-criteria APS manifestations for the detection of patients with APS. This article summarizes the studies analysed on the catastrophic APS, APS nephropathy and heart valve lesions, and presents the recommendations elaborated by the Task Force after this analysis. Lupus (2011) 20, 165-173.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Hematology

Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients

Romain Stammler, Yann Nguyen, Cecile Yelnik, Veronique Le Guern, Marc Lambert, Romain Paule, Eric Hachulla, Luc Mouthon, Anastasia Dupre, Felix Ackermann, Virginie Dufrost, Denis Wahl, Bertrand Godeau, Gaelle Leroux, Ygal Benhamou, Estibaliz Lazaro, Eric Daugas, Holy Bezanahary, Arsene Mekinian, Jean-Charles Piette, Nathalie Morel, Nathalie Costedoat-Chalumeau

Summary: This study analyzed the prevention of catastrophic antiphospholipid syndrome (CAPS), focusing on anticoagulation before CAPS episodes. The results indicated that the major precipitating factors of CAPS were infections, pregnancy, and surgery. Among patients with previous APS diagnosis, the proportion of using vitamin K antagonists (VKA) was low and many patients had a subtherapeutic international normalized ratio (INR) below 2, suggesting suboptimal anticoagulation management. These findings strongly suggest that inadequate anticoagulation can trigger CAPS.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Add to Collection

Article Medicine, General & Internal

Heart Valve Involvement in Patients with Antiphospholipid Syndrome: A Long-Term Follow-Up Study of a Single Centre

Isaac Pons, Joana Louro, Marta Sitges, Barbara Vidal, Ricard Cervera, Gerard Espinosa

Summary: This study describes the prevalence, clinical and laboratory features, and evolution of heart valve involvement in patients with APS. The results showed that 50% of APS patients had valve involvement, with most of them being female and having arterial hypertension and arterial thrombosis. The valve involvement group had a higher mortality rate.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Rheumatology

Catastrophic antiphospholipid syndrome with Epstein-Barr virus-associated hemophagocytosis: A clinicopathological conference

Aya Nawata, Rie Shirayama, Koichi Oshida, Tetsuji Sato, Takuma Ito, Eisuke Shiba, Koichi Kusuhara, Masanori Hisaoka

Summary: This case report highlights a challenging diagnosis and pathogenesis of catastrophic antiphospholipid syndrome and EBV-associated hemophagocytosis in a 14-year-old girl.

LUPUS (2022)

Add to Collection

Review Pharmacology & Pharmacy

Treatment of Refractory/High-Risk Pregnancies With Antiphospholipid Syndrome: A Systematic Review of the Literature

Ariela Hoxha, Daniela Tormene, Elena Campello, Paolo Simioni

Summary: This study conducted a systematic review on the additional treatments used in refractory and high-risk antiphospholipid antibody syndrome (APS) pregnancies. The results showed that combination therapy with IVIG and PEX achieved a 100% live birth rate in refractory APS pregnancies, while Pravastatin, IA, and PEX showed higher live birth rates in high-risk APS pregnancies.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Article Rheumatology

2023 ACR/EULAR antiphospholipid syndrome classification criteria

Medha Barbhaiya, Stephane Zuily, Ray Naden, Alison Hendry, Florian Manneville, Mary-Carmen Amigo, Zahir Amoura, Danieli Andrade, Laura Andreoli, Bahar Artim-Esen, Tatsuya Atsumi, Tadej Avcin, Michael H. Belmont, Maria Laura Bertolaccini, D. Ware Branch, Graziela Carvalheiras, Alessandro Casini, Ricard Cervera, Hannah Cohen, Nathalie Costedoat-Chalumeau, Mark Crowther, Guilherme de Jesus, Aurelien Delluc, Sheetal Desai, Maria De Sancho, Katrien M. Devreese, Reyhan Diz-Kucukkaya, Ali Duarte-Garcia, Camille Frances, David Garcia, Jean-Christophe Gris, Natasha Jordan, Rebecca K. Leaf, Nina Kello, Jason S. Knight, Carl Laskin, Alfred I. Lee, Kimberly Legault, Steve R. Levine, Roger A. Levy, Maarten Limper, Michael D. Lockshin, Karoline Mayer-Pickel, Jack Musial, Pier Luigi Meroni, Giovanni Orsolini, Thomas L. Ortel, Vittorio Pengo, Michelle Petri, Guillermo Pons-Estel, Jose A. Gomez-Puerta, Quentin Raimboug, Robert Roubey, Giovanni Sanna, Surya V. Seshan, Savino Sciascia, Maria G. Tektonidou, Angela Tincani, Denis Wahl, Rohan Willis, Cecile Yelnik, Catherine Zuily, Francis Guillemin, Karen Costenbader, Doruk Erkan

Summary: This study developed new APS classification criteria with high specificity, including clinical and laboratory domains, and improved classification accuracy through weighting and stratification.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Review Immunology

An advanced understanding of the heterogeneous clinical features of non-criteria obstetric antiphospholipid syndrome: Two case reports and a literature review

Xue Peng, Xi Tan, Aiyun Xing

Summary: Antiphospholipid syndrome (APS) is an acquired autoimmune disorder characterized by recurrent thrombosis and pregnancy complications. Obstetrical APS (OAPS) specifically refers to APS in pregnant women. The classification criteria for OAPS have generated discussion due to the possibility of excluding certain patients. This article presents two cases of non-criteria OAPS with severe complications and discusses the diagnosis, treatment, and prognosis of this unusual antenatal event. It also provides an overview of the pathogenetic mechanisms and clinical features of OAPS.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Bilateral adrenal hemorrhage: A rare presentation of catastrophic anti-phospholipid syndrome

Al-Ameen Oredegbe, Fabiana Maria Santelises Robledo, Krishnakumar Hongalgi, Geovani Faddoul, Swati Mehta

Summary: Catastrophic anti-phospholipid syndrome (CAPS) is a rare and fatal complication of antiphospholipid syndrome (APS) characterized by microvascular thrombosis in multiple sites leading to multi-organ damage. We present a challenging case of CAPS in a patient who initially presented with bilateral adrenal hemorrhage, making the diagnosis difficult. This case highlights the importance of considering APS in patients with multi-organ failure and multiple thromboses and hemorrhage.

AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

The Predictive Value of the aCL and Anti-β2GPI at the Time of Acute Deep Vein Thrombosis-A Two-Year Prospective Study

Katja Perdan-Pirkmajer, Polona Zigon, Anja Boc, Eva Podovsovnik, Sasa Cucnik, Alenka Mavri, Ziga Rotar, Ales Ambrozic

Summary: This study suggests that negative aCL and/or anti-beta 2GPI at the time of acute DVT may not require further aPL testing, while LA should be checked after discontinuation of anticoagulant therapy. Positive aCL and/or anti-beta 2GPI at the time of acute DVT have a strong positive predictive value for APS and may impact therapeutic decisions.

BIOMEDICINES (2021)

Add to Collection

Article Immunology

Persistence of antiphospholipid antibodies over time and its association with recurrence of clinical manifestations: A longitudinal study from a single centre

Giuseppe Barilaro, Emmanuel Coloma-Bazan, Alejandro Chacur, Carlo Della Rocca, Albert Perez-Isidro, Estibaliz Ruiz-Ortiz, Odette Vinas, Dolors Tassies Penella, Joan Carles Reverter, Alicia Molina Andujar, Ricard Cervera, Gerard Espinosa

Summary: The purpose of this study was to analyze the persistence of antiphospholipid antibodies (aPL) over time in patients with antiphospholipid syndrome (APS) and its association with clinical recurrence. The results showed that more than half of the patients maintained persistent positive aPLs over a long-term follow-up, and these patients were more prone to experience recurrence of clinical manifestations.

AUTOIMMUNITY REVIEWS (2022)

Add to Collection

Review Immunology

Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the CAPS Registry

Brenda Lopez-Benjume, Ignasi Rodriguez-Pinto, Mary Carmen Amigo, Doruk Erkan, Yehuda Shoenfeld, Ricard Cervera, Gerard Espinosa

Summary: This study utilized data from the CAPS Registry to describe the real-world experience of eculizumab use in patients with catastrophic antiphospholipid syndrome (CAPS). Eculizumab can be considered as a first-line or rescue therapy for CAPS patients who have failed previous treatments.

AUTOIMMUNITY REVIEWS (2022)

Add to Collection

Article Immunology

Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management

Michael A. Cole, Gloria F. Gerber, Shruti Chaturvedi

Summary: Complement is a major driver of antiphospholipid syndrome (APS) and a promising therapeutic target. Reliable, rapid-turnaround biomarkers are needed in APS to predict adverse clinical outcomes and determine who will benefit most from complement inhibition. Current studies highlight the inconsistencies in testing, suggesting that cell-based testing or multiplex panels may be most clinically relevant.

CLINICAL IMMUNOLOGY (2023)

Add to Collection

Article Rheumatology

The clinical significance of low complement levels in patients with catastrophic antiphospholipid syndrome: A descriptive analysis of 73 patients from the Catastrophic antiphospholipid syndrome registry

Ana Ponce, Ignasi Rodriguez-Pinto, Jose M. Basauli, Gerard Espinosa, Doruk Erkan, Yehuda Shoenfeld, Ricard Cervera

Summary: This study found that low levels of C3 and C4 plasma proteins are detected in 58% of episodes in patients with catastrophic antiphospholipid syndrome (CAPS). However, this decrease is not associated with clinical presentation, aPL positivity, or mortality.

LUPUS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Trophoblast Cell Function in the Antiphospholipid Syndrome

Svetlana Vrzic Petronijevic, Aleksandra Vilotic, Zanka Bojic-Trbojevic, Sanja Kostic, Milos Petronijevic, Ljiljana Vicovac, Milica Jovanovic Krivokuca

Summary: Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the presence of antiphospholipid antibodies (aPL). Women with APS are at high risk of recurrent early pregnancy loss and late obstetrical complications. In addition to vascular thrombosis, research has found that aPL has a direct negative effect on placental cells, which is a major mechanism of obstetric APS.

BIOMEDICINES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Understanding the Pathophysiology of Thrombotic APS through Animal Models

Alex A. Gandhi, Shanea K. Estes, Christine E. Rysenga, Jason S. Knight

Summary: Antiphospholipid syndrome (APS) is a leading cause of thrombosis, with pathogenic antibodies circulating at stable levels in blood, but thrombotic events often requiring a second hit. Investigators have turned to animal models to explore APS mechanisms, with each model having potential advantages and disadvantages.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Rheumatology

Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository

Elena Gkrouzman, Ecem Sevim, Jackie Finik, Danieli Andrade, Vittorio Pengo, Savino Sciascia, Maria G. Tektonidou, Amaia Ugarte, Cecilia B. Chighizola, H. Michael Belmont, Chary Lopez-Pedrera, Lanlan Ji, Paul Fortin, Maria Efthymiou, Guilherme Ramires de Jesus, D. Ware Branch, Cecilia Nalli, Michelle Petri, Esther Rodriguez, Ricard Cervera, Jason S. Knight, Tatsuya Atsumi, Rohan Willis, Maria Laura Bertolaccini, Hannah Cohen, Jacob Rand, Doruk Erkan

Summary: The study revealed that approximately 80% of patients with persistently antiphospholipid antibody (aPL) positive remained stable in their aPL profiles over a 5-year follow-up period. Additionally, the decrease in triple aPL positivity at baseline was associated with increased odds of stable aPL profile.

JOURNAL OF RHEUMATOLOGY (2021)

Add to Collection

Article Ophthalmology

Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis

Lucia Miguel-Escuder, Amanda Garcia Tirado, Maria Sainz-de-la-Maza, Gerard Espinosa, Aina Moll-Udina, Victor Llorenc, Alba Parrado-Carrillo, Alfredo Adan

Summary: This study retrospectively describes three cases of Anti-TNF-alpha-induced lupus (ATIL) in patients with non-infectious uveitis (NIU), who developed antinuclear antibody (ANA) and anti-dsDNA antibody positivity, arthritis, and in one case, skin lesions under adalimumab treatment. The condition resolved in all patients after adalimumab withdrawal, with one patient requiring corticosteroids, two patients requiring non-steroidal anti-inflammatory drugs, and one patient requiring hydroxychloroquine. None of the patients required another immunosuppressive drug. Two patients were able to continue follow-up without anti-TNF-alpha therapy, while the remaining patient switched to another anti-TNF-alpha treatment (golimumab). A review of the literature and comparison with previous ATIL cases was also conducted.

EUROPEAN JOURNAL OF OPHTHALMOLOGY (2023)

Add to Collection

Article Rheumatology

Clinico-pathological phenotypes of systemic sclerosis-associated myopathy: analysis of a large multicentre cohort

Ana Matas-Garcia, Alfredo Guillen-Del-Castillo, Boris Kisluk, Albert Selva-O'Callaghan, Gerard Espinosa, Sergio Prieto-Gonzalez, Pedro Moreno Lozano, Gloria Garrabou, Josep Maria Grau-Junyent, Carmen Pilar Simeon-Aznar, Jose C. Milisenda

Summary: This study analyzed the clinico-serological and histological phenotypes of SSc patients with associated myopathy. The patients were divided into two subgroups based on histological findings: fibrosing and inflammatory. Significant differences were found in clinical data, antibody profile, electrophysiologic studies, treatment response, mortality, and survival between the two groups.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

Patients with laboratory criteria of anti-phospholipid syndrome and 'non-criteria' manifestations: a multicenter cohort

G. Pires da Rosa, E. Ferreira, B. Sousa-Pinto, P. Bettencourt, G. Espinosa, R. Cervera

Summary: This study analyzed a cohort of patients with laboratory criteria for anti-phospholipid syndrome (APS) but only presenting "non-criteria" clinical manifestations. The patients were compared with definite APS patients. The results showed that these "clinical non-criteria" patients had mainly hematological and neurological involvements, with significant treatment use. Some patients may progress to future systemic lupus erythematosus (SLE).

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

The adjusted Global Anti-Phospholipid Syndrome Score as predictor of damage accrual measured by Damage Index for APS: a longitudinal study

Giuseppe Barilaro, Carlo Della Rocca, Alexandra Esteves, Ricard Cervera, Gerard Espinosa

Summary: This study analyzed the association between the average 'adjusted' Global APS Score (aGAPSS) and the change in Damage Index for APS (DIAPS) in patients with thrombotic and non-thrombotic APS. The results showed that a higher average aGAPSS value was associated with an increase in DIAPS during follow-up, suggesting that the average aGAPSS score can predict the increase in DIAPS.

RHEUMATOLOGY (2023)

Add to Collection

Article Immunology

Whole blood transcriptome identifies interferon-regulated genes as key drivers in thrombotic primary antiphospholipid syndrome

Kleio-Maria Verrou, Petros P. Sfikakis, Maria G. Tektonidou

Summary: In this study, gene signatures associated with thrombotic primary antiphospholipid syndrome (thrPAPS) were identified using whole blood RNA-sequencing. The differentially expressed genes, including those related to interferon and interferon signaling pathway, showed high accuracy in discriminating thrPAPS patients from healthy controls. Moreover, these genes were found to be highly expressed in subgroups with venous thrombosis, triple antiphospholipid antibody positivity, and recurrent thrombosis, providing potential treatment implications.

JOURNAL OF AUTOIMMUNITY (2023)

Add to Collection

Article Immunology

Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques

Eleana Bolla, Nikolaos Tentolouris, Petros P. Sfikakis, Maria G. Tektonidou

Summary: This study aimed to evaluate the prevalence of Metabolic Syndrome (MetS) in antiphospholipid syndrome (APS) patients and its associations with cardiovascular risk biomarkers, physical activity, and subclinical atherosclerosis. The results showed that MetS was present in approximately one-fourth of APS patients and was associated with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and subclinical atherosclerosis. This suggests that MetS plays an important role in cardiovascular risk stratification and management in APS.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Patterns and factors associated with pneumococcal vaccination in a prospective cohort of 1,697 patients with rheumatoid arthritis

Konstantinos Thomas, Argyro Lazarini, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, Alexandros A. Drosos, Argyro Repa, Ainour Molla Ismail Sali, Prodromos Sidiropoulos, Panagiota Tsatsani, Sousana Gazi, Kalliopi Fragkiadaki, Maria G. Tektonidou, Petros P. Sfikakis, Pelagia Katsimbri, Dimitrios Boumpas, Evangelia Argyriou, Kyriaki A. Boki, Konstantina Karagianni, Christina Katsiari, Gerasimos Evangelatos, Alexios Iliopoulos, Eleftheria P. Grika, Panagiotis G. Vlachoyiannopoulos, Theodoros Dimitroulas, Alexandros Garyfallos, Konstantinos Melissaropoulos, Panagiotis Georgiou, Constantinos Georganas, Periklis Vounotrypidis, Konstantinos Ntelis, Maria Areti, George D. Kitas, Dimitrios Vassilopoulos

Summary: The rate of pneumococcal vaccination among rheumatoid arthritis (RA) patients remains suboptimal, with 40% remaining unvaccinated. Severe disease, bDMARD use, comorbidities, and influenza vaccination were significant factors associated with pneumococcal vaccination, highlighting the need for cultivating a vaccination culture in RA patients.

FRONTIERS IN MEDICINE (2023)

Add to Collection

Article Rheumatology

Tocilizumab in Behcet Disease: A Multicenter Study of 30 Patients

Mohamed-Yacine Khitri, Alessandra Bartoli, Georgina Maalouf, Alban Deroux, Carlo Salvarani, Giacomo Emmi, Omer Karadag, Gerard Espinosa, Mathilde Leclercq, Gabriele Simonini, Mathieu Vautier, Patrice Cacoub, David Saadoun

Summary: This study evaluated the efficacy of tocilizumab in patients with refractory Behcet disease. The results showed that 83% of patients responded to tocilizumab, with 60% achieving complete response and 23% achieving partial response. Tocilizumab also significantly reduced steroid dosage and the need for concomitant disease-modifying antirheumatic drugs. However, a small number of patients experienced mild to moderate side effects and serious adverse events.

JOURNAL OF RHEUMATOLOGY (2023)

Add to Collection

Review Medicine, General & Internal

Microwave Radiometry for the Diagnosis and Monitoring of Inflammatory Arthritis

Katerina Laskari, Elias Siores, Maria M. Tektonidou, Petros P. Sfikakis

Summary: The ability of microwave radiometry (MWR) to accurately detect in-depth temperature changes in human tissues is being investigated for its application in the diagnosis and monitoring of inflammatory arthritis. Studies have shown promising results, suggesting that MWR can be a useful tool for the differential diagnosis of arthritis and for assessing inflammation at both joint and patient levels. However, further studies with larger patient populations are needed to confirm these findings and overcome the current limitations of MWR devices.

DIAGNOSTICS (2023)

Add to Collection

Article Biology

Late-Onset Psoriatic Arthritis: Are There Any Distinct Characteristics? A Retrospective Cohort Data Analysis

Chrysoula G. Gialouri, Gerasimos Evangelatos, Alexios Iliopoulos, Maria G. Tektonidou, Petros P. Sfikakis, George E. Fragoulis, Elena Nikiphorou

Summary: With increasing life expectancy, psoriatic arthritis (PsA) in older individuals becomes more prevalent. We compared the clinical features, treatment approaches, and comorbidity profiles between late-onset and earlier-onset PsA patients. Late-onset PsA patients had lower odds of enthesitis but higher risks of dyslipidemia and major adverse cardiovascular events during the disease course.

LIFE-BASEL (2023)

Add to Collection

Article Rheumatology

Lipid management in systemic lupus erythematosus according to risk classifiers suggested by the European Society of Cardiology and disease-related risk factors reported by the EULAR recommendations

George C. Drosos, George Konstantonis, Petros P. Sfikakis, Maria G. Tektonidou

Summary: This study examined the eligibility for lipid-lowering therapy (LLT) in SLE patients according to SCORE, with the addition of vascular ultrasound and disease-related features. The results showed that disease-related and ultrasound features can help improve LLT decision making in SLE.

RMD OPEN (2023)

Add to Collection

Article Rheumatology

Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE

Stylianos Panopoulos, George C. Drosos, George Konstantonis, Petros P. Sfikakis, Maria G. Tektonidou

Summary: This study found that generic and disease-adapted cardiovascular risk (CVR) prediction tools can predict the progression of subclinical atherosclerosis in patients with systemic lupus erythematosus (SLE). Using disease-adapted CVR scores such as QRISK3 or mFRS, as well as monitoring glucocorticoid exposure and the presence of antiphospholipid antibodies, can improve CVR assessment and management in SLE patients.

LUPUS SCIENCE & MEDICINE (2023)

Add to Collection

Article Rheumatology

Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism

Jose Manuel Mascaro, Ignasi Rodriguez-Pinto, Gabriela Poza, Anna Mensa-Vilaro, Julian Fernandez-Martin, Luis Caminal-Montero, Gerard Espinosa, Jose Hernandez-Rodriguez, Marina Diaz, Joana Rita-Marques, Raimon Sanmarti, Santos Castaneda, Dolores Colunga, Ruben Coto-Hernandez, Patricia Fanlo, Jose Ignacio Elejalde, Segundo Bujan, Ignasi Figueras, Francisco Manuel Marco, Mariano Andres, Silvia Suarez, Andres Gonzalez-Garcia, Xavier Fusta-Novell, Clara Garcia-Belando, Ana Granados, Maria Teresa Fernandez-Figueras, Neus Quilis, Maria Orriols-Caba, Ricardo Gomez de la Torre, Maria Cinta Cid, Georgina Espigol-Frigole, Alba Alvarez-Abella, Eztizen Labrador, Maria Rozman, Monica Lopez-Guerra, Paola Castillo, Jose R. Alamo-Moreno, Eva Gonzalez-Roca, Susana Plaza, Virginia Fabregat, Rocio Lara, Esther F. Vicente-Rabaneda, Sonia Tejedor-Vaquero, Giuliana Magri, Nuria Bonet, Manuel Solis-Moruno, Andrea Cerutti, Oscar Fornas, Ferran Casals, Jordi Yague, Juan Arostegui

Summary: Thirty patients with adult-onset autoinflammatory diseases were definitively diagnosed with VEXAS syndrome through genetic analyses. Patients presented with late-onset disease and symptoms including cutaneous lesions, fever, pulmonary manifestations, and arthritis. The UBA1 variants were detected in both hematopoietic and non-hematopoietic tissues.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Dermatology

Pregnancy outcomes in patients exposed to baricitinib in clinical trials and during postmarketing surveillance

Bianca Bergamini, Julien Seneschal, Kristin J. Meyers, Frederick Durand, Ewa Haladyj, Gerard Espinosa, Jacob P. Thyssen

Summary: A total of 117 pregnancies with exposure to baricitinib were analyzed, and the clinical outcomes were found to be comparable to other targeted therapies for immune-mediated diseases or general population.

BRITISH JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Editorial Material Rheumatology

Combination of old and new drugs to improve renal outcome in SLE patients

Gerard Espinosa, Ricard Cervera

RHEUMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.